JP2009536033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536033A5 JP2009536033A5 JP2009509770A JP2009509770A JP2009536033A5 JP 2009536033 A5 JP2009536033 A5 JP 2009536033A5 JP 2009509770 A JP2009509770 A JP 2009509770A JP 2009509770 A JP2009509770 A JP 2009509770A JP 2009536033 A5 JP2009536033 A5 JP 2009536033A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- degrading
- tame
- domain
- cell wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 68
- 210000002421 cell wall Anatomy 0.000 claims description 26
- 230000000593 degrading effect Effects 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 230000001580 bacterial effect Effects 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 17
- 108010013639 Peptidoglycan Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 101710154270 Nuclear protein UL4 homolog Proteins 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 230000000249 desinfective effect Effects 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 101000814063 Salmonella phage P22 Uncharacterized 6.6 kDa protein in eae-abc2 intergenic region Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 108090000988 Lysostaphin Proteins 0.000 description 5
- 108700023418 Amidases Proteins 0.000 description 4
- 102000005922 amidase Human genes 0.000 description 4
- 230000002101 lytic effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000005255 gram-positive cell Anatomy 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 101100351191 Autographa californica nuclear polyhedrosis virus PCNA gene Proteins 0.000 description 1
- 101000870242 Bacillus phage Nf Tail knob protein gp9 Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000701553 Myoviridae Species 0.000 description 1
- 101150050790 ORF49 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000702072 Podoviridae Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702202 Siphoviridae Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191965 Staphylococcus carnosus Species 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 241000724233 Staphylococcus virus 11 Species 0.000 description 1
- 101000814062 Streptomyces lividans Uncharacterized 6.0 kDa protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79788506P | 2006-05-05 | 2006-05-05 | |
| US60/797,885 | 2006-05-05 | ||
| US90934007P | 2007-03-30 | 2007-03-30 | |
| US60/909,340 | 2007-03-30 | ||
| PCT/US2007/010972 WO2007130655A2 (en) | 2006-05-05 | 2007-05-04 | Phage derived antimicrobial activities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013206059A Division JP5882968B2 (ja) | 2006-05-05 | 2013-10-01 | ファージに由来する抗微生物活性 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536033A JP2009536033A (ja) | 2009-10-08 |
| JP2009536033A5 true JP2009536033A5 (OSRAM) | 2010-06-17 |
| JP5383481B2 JP5383481B2 (ja) | 2014-01-08 |
Family
ID=38668376
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009509770A Expired - Fee Related JP5383481B2 (ja) | 2006-05-05 | 2007-05-04 | ファージに由来する抗微生物活性 |
| JP2013206059A Active JP5882968B2 (ja) | 2006-05-05 | 2013-10-01 | ファージに由来する抗微生物活性 |
| JP2016019695A Expired - Fee Related JP6416803B2 (ja) | 2006-05-05 | 2016-02-04 | ファージに由来する抗微生物活性 |
| JP2018188797A Expired - Fee Related JP6685360B2 (ja) | 2006-05-05 | 2018-10-04 | ファージに由来する抗微生物活性 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013206059A Active JP5882968B2 (ja) | 2006-05-05 | 2013-10-01 | ファージに由来する抗微生物活性 |
| JP2016019695A Expired - Fee Related JP6416803B2 (ja) | 2006-05-05 | 2016-02-04 | ファージに由来する抗微生物活性 |
| JP2018188797A Expired - Fee Related JP6685360B2 (ja) | 2006-05-05 | 2018-10-04 | ファージに由来する抗微生物活性 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US8202516B2 (OSRAM) |
| EP (1) | EP2037946B2 (OSRAM) |
| JP (4) | JP5383481B2 (OSRAM) |
| CN (3) | CN101437532B (OSRAM) |
| CA (1) | CA2651125C (OSRAM) |
| DK (1) | DK2037946T3 (OSRAM) |
| ES (1) | ES2536852T3 (OSRAM) |
| MX (1) | MX2008014150A (OSRAM) |
| PT (1) | PT2037946E (OSRAM) |
| WO (1) | WO2007130655A2 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007061929A1 (de) * | 2007-12-21 | 2009-06-25 | Profos Ag | Proteasestabile Zellwand lysierende Enzyme |
| EP2157100A1 (en) * | 2008-08-19 | 2010-02-24 | Profos AG | Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins |
| CA2739717A1 (en) * | 2008-10-10 | 2010-04-15 | Lusomedicamenta, S.A. | Antibacterial phage peptides and methods of use thereof |
| EP2338916A1 (en) | 2009-12-23 | 2011-06-29 | Hyglos Invest GmbH | Chimeric polypeptides and their use in bacterial decoloniation |
| EP2397548A1 (en) | 2010-06-18 | 2011-12-21 | Hyglos Invest GmbH | Methods of generating and screening for lytic chimeric polypeptides |
| EP3443970B1 (en) | 2010-09-17 | 2020-09-09 | Tecnifar-Indústria Técnica Farmacêutica, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
| EP2697387B1 (en) * | 2011-04-12 | 2021-09-15 | Bactoclear Holdings PTE. LTD. | Chimeric antibacterial polypeptides |
| PL394619A1 (pl) | 2011-04-19 | 2012-10-22 | Miedzynarodowy Instytut Biologii Molekularnej I Komórkowej | Sposób proteolizy, peptydaza, kompozycja do stosowania jako srodek bakteriostatyczny lub bakteriobójczy, zestaw oraz zastosowania aktywnej formy LytM z S. aureus lub jej pochodnej |
| AU2013240280A1 (en) | 2012-03-27 | 2014-10-16 | Genentech, Inc. | Improved harvest operations for recombinant proteins |
| KR101381336B1 (ko) | 2012-06-25 | 2014-04-25 | 주식회사 씨티씨바이오 | 신규한 박테리오파지 ｐｖｐ-1 및 이의 비브리오 파라헤몰리티쿠스 증식 억제 용도 |
| KR101466620B1 (ko) | 2012-06-22 | 2014-11-28 | 주식회사 씨티씨바이오 | 신규한 박테리오파지 및 이의 아에로모나스 히드로필라 증식 억제 용도 |
| WO2013191363A1 (ko) * | 2012-06-22 | 2013-12-27 | 주식회사 씨티씨바이오 | 신규한 박테리오파지 및 병원성 박테리아 증식 억제 용도 |
| US8980614B2 (en) * | 2012-09-06 | 2015-03-17 | The United States Of America, As Represented By The Secretary Of Agriculture | Staphylococcus haemolyticus prophage φSH2 endolysin is lytic for Staphylococcus aureus |
| CN112626055A (zh) * | 2014-05-14 | 2021-04-09 | 达特茅斯学院理事会 | 去免疫化溶葡萄球菌酶和使用方法 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US10689670B2 (en) * | 2016-06-14 | 2020-06-23 | Dsm Ip Assets B.V. | Recombinant yeast cell |
| EP3503913A4 (en) * | 2016-08-26 | 2020-05-27 | GangaGen, Inc. | STAPHTAMACTIVITY ON ORGANIC FILMS |
| CN106635942B (zh) * | 2016-12-05 | 2020-05-29 | 齐鲁工业大学 | 一种芽孢表面稳定展示海藻糖合酶的工程菌及其构建方法 |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11236314B2 (en) * | 2017-03-30 | 2022-02-01 | Bactoclear Holdings Pte. Ltd | Chimeric lysm polypeptides |
| KR20200012844A (ko) * | 2017-04-03 | 2020-02-05 | 사시나파스 컴퍼니 리미티드 | 조작된 그람-음성 엔도리신 |
| CN107502603B (zh) * | 2017-09-06 | 2018-06-05 | 江苏省农业科学院 | 一种大肠杆菌裂解酶及其制备方法与应用 |
| CN107828769B (zh) * | 2017-09-28 | 2021-03-02 | 昆明理工大学 | 一种耐热裂解酶MMPpgh和编码此酶的多核苷酸 |
| EP3723488B1 (en) | 2017-12-14 | 2025-07-30 | Bactoclear Holdings Pte Ltd. | Therapeutic bacteriocins |
| JP7034724B2 (ja) * | 2018-01-16 | 2022-03-14 | 花王株式会社 | ケラチン断片の製造方法 |
| CN113366103A (zh) | 2018-12-21 | 2021-09-07 | 诺维信公司 | 具有肽聚糖降解活性的多肽以及编码其的多核苷酸 |
| MA55951A (fr) * | 2019-05-08 | 2022-03-23 | Biontech R&D Austria Gmbh | Nouveau gardnerella endolysins et utilisations correspondantes |
| US20220333120A1 (en) * | 2019-09-11 | 2022-10-20 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Bactericidal phage vectors |
| PL243303B1 (pl) * | 2019-10-13 | 2023-07-31 | Miedzynarodowy Inst Biologii Molekularnej I Komorkowej | Rekombinowany polipeptyd do zastosowania do leczenia, kompozycje go zawierające oraz jego zastosowania |
| WO2021084558A2 (en) * | 2019-10-31 | 2021-05-06 | Bactoclear Holdings Pte. Ltd | Chimeric proteins for selective lysis of bacteria |
| CN111187765B (zh) * | 2020-02-17 | 2022-07-15 | 西北农林科技大学 | 一种反刍动物瘤胃特异溶菌酶lyz1及其应用 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US20250019667A1 (en) * | 2021-05-13 | 2025-01-16 | Forge Biologics, Inc. | Adenoviral helper plasmid |
| CN116732013B (zh) * | 2022-03-01 | 2025-07-25 | 百葵锐(深圳)生物科技有限公司 | 具有抗菌活性的细胞壁降解酶 |
| AU2024270871A1 (en) * | 2023-05-15 | 2025-11-20 | Topaz Biosciences, Inc. | Enzymatically active domains from anti-staphylococcal phage proteins |
| WO2024263589A1 (en) | 2023-06-20 | 2024-12-26 | Topaz Biosciences, Inc. | Recombinant cell wall hydrolases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997008553A1 (en) * | 1995-08-22 | 1997-03-06 | The Regents Of The University Of California | Targeting of proteins to the cell wall of gram-positive bacteria |
| AU1705097A (en) * | 1996-01-19 | 1997-08-11 | Novo Nordisk Biotech, Inc. | Bacterial donor cell useful in conjugation |
| CA2297083C (en) * | 1997-07-23 | 2007-10-30 | Ambi Inc. | Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections |
| AU4350400A (en) * | 1999-04-16 | 2000-11-02 | Osel, Inc. | A method for improving the half-life of soluble viral-specific ligands on mucosal membranes |
| US6831063B1 (en) * | 1999-08-31 | 2004-12-14 | The Wistar Institute Of Anatomy And Biology | Bridging Integrator-2(Bin2) nucleic acid molecules and proteins and uses therefor |
| US20050214773A1 (en) * | 2001-09-21 | 2005-09-29 | Affinium Pharmaceuticals, Inc. | Novel purified polypeptides from bacteria |
| JPWO2004020635A1 (ja) * | 2002-08-28 | 2005-12-15 | 株式会社テクノネットワーク四国 | バクテリオファージおよび細菌感染症治療剤 |
| US7569223B2 (en) * | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
| IE20060488A1 (en) * | 2006-06-29 | 2008-01-09 | Teagasc Agric Food Dev Authori | Recombinant staphylococcal phage lysin as an antibacterial agent |
-
2007
- 2007-05-04 DK DK07794592.1T patent/DK2037946T3/en active
- 2007-05-04 EP EP07794592.1A patent/EP2037946B2/en not_active Not-in-force
- 2007-05-04 US US12/299,601 patent/US8202516B2/en active Active
- 2007-05-04 CN CN2007800162540A patent/CN101437532B/zh not_active Expired - Fee Related
- 2007-05-04 ES ES07794592.1T patent/ES2536852T3/es active Active
- 2007-05-04 PT PT77945921T patent/PT2037946E/pt unknown
- 2007-05-04 CA CA2651125A patent/CA2651125C/en active Active
- 2007-05-04 WO PCT/US2007/010972 patent/WO2007130655A2/en not_active Ceased
- 2007-05-04 CN CN201610182492.XA patent/CN105884904B/zh not_active Expired - Fee Related
- 2007-05-04 CN CN201310322283.7A patent/CN103436507B/zh not_active Expired - Fee Related
- 2007-05-04 JP JP2009509770A patent/JP5383481B2/ja not_active Expired - Fee Related
- 2007-05-04 MX MX2008014150A patent/MX2008014150A/es active IP Right Grant
-
2012
- 2012-05-21 US US13/476,750 patent/US8748150B2/en active Active
-
2013
- 2013-10-01 JP JP2013206059A patent/JP5882968B2/ja active Active
-
2014
- 2014-05-15 US US14/278,574 patent/US9622486B2/en not_active Expired - Fee Related
-
2016
- 2016-02-04 JP JP2016019695A patent/JP6416803B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-07 US US15/481,767 patent/US10278398B2/en active Active
-
2018
- 2018-10-04 JP JP2018188797A patent/JP6685360B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-08 US US16/378,159 patent/US20190297896A1/en not_active Abandoned
-
2021
- 2021-09-01 US US17/464,019 patent/US20220053775A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536033A5 (OSRAM) | ||
| Abdelrahman et al. | Phage-encoded endolysins | |
| JP6685360B2 (ja) | ファージに由来する抗微生物活性 | |
| Rodríguez-Rubio et al. | Phage lytic proteins: biotechnological applications beyond clinical antimicrobials | |
| Carvalho et al. | Bacteriophages and their derivatives for the treatment and control of food-producing animal infections | |
| Haddad Kashani et al. | Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies | |
| Donovan | Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications | |
| ES2560262T3 (es) | Bacteriófago o proteína lítica derivados del bacteriófago que es eficaz para el tratamiento de la biopelícula de Staphylococcus aureus | |
| Linger et al. | Towards next generation maggot debridement therapy: transgenic Lucilia sericata larvae that produce and secrete a human growth factor | |
| US8383102B2 (en) | Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens | |
| JP6769871B2 (ja) | Ｅ．ｃｏｌｉ感染のファージを用いての治療 | |
| Song et al. | Staphylococcus aureus and biofilms: transmission, threats, and promising strategies in animal husbandry | |
| RS55230B1 (sr) | Himerni polipeptidi i njihova primena u bakterijskoj dekolonizaciji | |
| JP6755801B2 (ja) | 治療的な使用のための、核酸送達のための治療用ファージおよび方法 | |
| EP2661495A1 (en) | Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens | |
| Golban et al. | Phage-derived endolysins against resistant Staphylococcus spp.: a review of features, antibacterial activities, and recent applications | |
| JP2020527551A5 (OSRAM) | ||
| Vulikh et al. | Effect of tracheal antimicrobial peptide on the development of Mannheimia haemolytica pneumonia in cattle | |
| Vander Elst et al. | Potential therapeutic application of bacteriophages and phage-derived endolysins as alternative treatment of bovine mastitis | |
| US20240148840A1 (en) | Chimeric endolysin polypeptide | |
| Shrivastava et al. | Enzymes in pharmaceutical industry | |
| Abdelrahman et al. | Phage-Encoded Endolysins. Antibiotics 2021, 10, 124 | |
| US20240409910A1 (en) | Recombinant polypeptide for use as a medicine, antiseptic agent, antibacterial agent, anti-inflammatory agent, compositions comprising it and uses thereof | |
| Cardoso et al. | Transgenic technology: the strategy for the control and prevention of bovine staphylococcal mastitis? | |
| WO2021079986A1 (ja) | バクテリオファージ組成物 |